Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTIOFLAM: Tiotropium Anti-inflammatory Effects in COPD
NCT04061161Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tiotropium respimat with Placebo respimat (2 arms). Primary endpoint: Change in concentration of TNF-alpha (mRNA level) in induced sputum at 6 weeks. Started Aug 2019; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04061161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061161.